Big Cardio Medtechs Are Moving ESG Agenda To Center Stage In 2022
In Vivo outlines major trends shaping the top 15 cardiovascular device companies included in the latest Medtech 100 rankings. They include a growing need to reach underserved patient populations, ongoing staffing and other challenges created by the COVID-19 pandemic, and reimbursement obstacles.
You may also be interested in...
Nick West, chief medical officer for Abbott’s vascular business talked to Medtech Insight about Abbott’s efforts to improve the assessment and treatment of vascular disease long before patients need an intervention.
A new analysis from Wells Fargo found that the big medtech stocks typically perform at least as well as the overall market when inflationary expectations are high, but 2021 defied that trend.
Paris-based Cardiologs is developing machine learning software to analyze electrocardiogram waveforms to detect arrhythmias.